Reviewing GeneDx (NASDAQ:WGS) & Joint (NASDAQ:JYNT)

Joint (NASDAQ:JYNT) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Joint and GeneDx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1	2	0	0	1.67
GeneDx	1	0	7	1	2.89

GeneDx has a consensus price target of $89.57, indicating a potential downside of 11.40%. Given GeneDx’s stronger consensus rating and higher probable upside, analysts clearly believe GeneDx is more favorable than Joint.

Valuation & Earnings

This table compares Joint and GeneDx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90 million	2.17	$2.91 million	$0.27	31.26
GeneDx	$427.54 million	7.05	-$21.02 million	($3.64)	-27.77

Joint has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Joint and GeneDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
GeneDx	-23.41%	4.12%	2.26%

Institutional and Insider Ownership

76.9% of Joint shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 30.2% of Joint shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Joint has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.

Summary

Joint beats GeneDx on 8 of the 15 factors compared between the two stocks.

About Joint

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.